#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|


#Text=[0249] Published United States paent application 2002/0106705 also discloses that: "Pentafluorophenylsulfonamidobenzenes and related sulfhydryl and disulfide modifying agents (see, e.g., compound 1; 2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene . . . prevent microtubule formation by selectively covalently modifying .beta.
1-1	0-1	[	_	
1-2	1-5	0249	_	
1-3	5-6	]	_	
1-4	7-16	Published	_	
1-5	17-23	United	_	
1-6	24-30	States	_	
1-7	31-36	paent	_	
1-8	37-48	application	_	
1-9	49-53	2002	_	
1-10	53-54	/	_	
1-11	54-61	0106705	_	
1-12	62-66	also	_	
1-13	67-76	discloses	_	
1-14	77-81	that	_	
1-15	81-82	:	_	
1-16	83-84	"	_	
1-17	84-120	Pentafluorophenylsulfonamidobenzenes	_	
1-18	121-124	and	_	
1-19	125-132	related	_	
1-20	133-143	sulfhydryl	_	
1-21	144-147	and	_	
1-22	148-157	disulfide	_	
1-23	158-167	modifying	_	
1-24	168-174	agents	_	
1-25	175-176	(	_	
1-26	176-179	see	_	
1-27	179-180	,	_	
1-28	181-184	e.g	_	
1-29	184-185	.	_	
1-30	185-186	,	_	
1-31	187-195	compound	_	
1-32	196-197	1	_	
1-33	197-198	;	_	
1-34	199-200	2	_	
1-35	200-201	-	_	
1-36	201-207	fluoro	_	
1-37	207-208	-	_	
1-38	208-209	1	_	
1-39	209-210	-	_	
1-40	210-217	methoxy	_	
1-41	217-218	-	_	
1-42	218-219	4	_	
1-43	219-220	-	_	
1-44	220-255	pentafluorophenylsulfonamidobenzene	_	
1-45	256-257	.	_	
1-46	258-259	.	_	
1-47	260-261	.	_	
1-48	262-269	prevent	_	
1-49	270-281	microtubule	_	
1-50	282-291	formation	_	
1-51	292-294	by	_	
1-52	295-306	selectively	_	
1-53	307-317	covalently	_	
1-54	318-327	modifying	_	
1-55	328-329	.	_	
1-56	329-333	beta	_	
1-57	333-334	.	_	

#Text=-tubulin.
2-1	334-335	-	_	
2-2	335-342	tubulin	_	
2-3	342-343	.	_	

#Text=For example, compound 1 does not covalently modify all of the five known .beta.
3-1	344-347	For	_	
3-2	348-355	example	_	
3-3	355-356	,	_	
3-4	357-365	compound	_	
3-5	366-367	1	_	
3-6	368-372	does	_	
3-7	373-376	not	_	
3-8	377-387	covalently	_	
3-9	388-394	modify	_	
3-10	395-398	all	_	
3-11	399-401	of	_	
3-12	402-405	the	_	
3-13	406-410	five	_	
3-14	411-416	known	_	
3-15	417-418	.	_	
3-16	418-422	beta	_	
3-17	422-423	.	_	

#Text=-tubulin isotypes.
4-1	423-424	-	_	
4-2	424-431	tubulin	_	
4-3	432-440	isotypes	_	
4-4	440-441	.	_	

#Text=Instead, binding is restricted to those .beta.
5-1	442-449	Instead	_	
5-2	449-450	,	_	
5-3	451-458	binding	_	
5-4	459-461	is	_	
5-5	462-472	restricted	_	
5-6	473-475	to	_	
5-7	476-481	those	_	
5-8	482-483	.	_	
5-9	483-487	beta	_	
5-10	487-488	.	_	

#Text=-tubulin isotypes that have a cysteine residue at amino acid position 239 in .beta.
6-1	488-489	-	_	
6-2	489-496	tubulin	_	
6-3	497-505	isotypes	_	
6-4	506-510	that	_	
6-5	511-515	have	_	
6-6	516-517	a	_	
6-7	518-526	cysteine	_	
6-8	527-534	residue	_	
6-9	535-537	at	_	
6-10	538-543	amino	_	
6-11	544-548	acid	_	
6-12	549-557	position	_	
6-13	558-561	239	_	
6-14	562-564	in	_	
6-15	565-566	.	_	
6-16	566-570	beta	_	
6-17	570-571	.	_	

#Text=-tubulin.
7-1	571-572	-	_	
7-2	572-579	tubulin	_	
7-3	579-580	.	_	

#Text=Such isotypes include .beta.1, .beta.2 and .beta.4-tubulin.
8-1	581-585	Such	_	
8-2	586-594	isotypes	_	
8-3	595-602	include	_	
8-4	603-604	.	_	
8-5	604-608	beta	_	
8-6	608-610	.1	_	
8-7	610-611	,	_	
8-8	612-613	.	_	
8-9	613-617	beta	_	
8-10	617-619	.2	_	
8-11	620-623	and	_	
8-12	624-625	.	_	
8-13	625-629	beta	_	
8-14	629-631	.4	_	
8-15	631-632	-	_	
8-16	632-639	tubulin	_	
8-17	639-640	.	_	

#Text=The other two isotypes (.beta.3 and .beta.5) have a serine residue at this particular position (Shan et al., Proc.
9-1	641-644	The	_	
9-2	645-650	other	_	
9-3	651-654	two	_	
9-4	655-663	isotypes	_	
9-5	664-665	(	_	
9-6	665-666	.	_	
9-7	666-670	beta	_	
9-8	670-672	.3	_	
9-9	673-676	and	_	
9-10	677-678	.	_	
9-11	678-682	beta	_	
9-12	682-684	.5	_	
9-13	684-685	)	_	
9-14	686-690	have	_	
9-15	691-692	a	_	
9-16	693-699	serine	_	
9-17	700-707	residue	_	
9-18	708-710	at	_	
9-19	711-715	this	_	
9-20	716-726	particular	_	
9-21	727-735	position	_	
9-22	736-737	(	_	
9-23	737-741	Shan	_	
9-24	742-744	et	_	
9-25	745-747	al	_	
9-26	747-748	.	_	
9-27	748-749	,	_	
9-28	750-754	Proc	_	
9-29	754-755	.	_	

#Text=Nat'l Acad.
10-1	756-761	Nat'l	_	
10-2	762-766	Acad	_	
10-3	766-767	.	_	

#Text=Sci USA 96:5686-5691 (1999)).
11-1	768-771	Sci	_	
11-2	772-775	USA	_	
11-3	776-778	96	_	
11-4	778-779	:	_	
11-5	779-783	5686	_	
11-6	783-784	-	_	
11-7	784-788	5691	_	
11-8	789-790	(	_	
11-9	790-794	1999	_	
11-10	794-795	)	_	
11-11	795-796	)	_	
11-12	796-797	.	_	

#Text=It is notable that no other cellular proteins are modified by compound 1."
#Text=[0250] Published United States paent application 2002/0106705 relates primarily to a " . . . . a .beta.
12-1	798-800	It	_	
12-2	801-803	is	_	
12-3	804-811	notable	_	
12-4	812-816	that	_	
12-5	817-819	no	_	
12-6	820-825	other	_	
12-7	826-834	cellular	_	
12-8	835-843	proteins	_	
12-9	844-847	are	_	
12-10	848-856	modified	_	
12-11	857-859	by	_	
12-12	860-868	compound	_	
12-13	869-870	1	_	
12-14	870-871	.	_	
12-15	871-872	"	_	
12-16	873-874	[	_	
12-17	874-878	0250	_	
12-18	878-879	]	_	
12-19	880-889	Published	_	
12-20	890-896	United	_	
12-21	897-903	States	_	
12-22	904-909	paent	_	
12-23	910-921	application	_	
12-24	922-926	2002	_	
12-25	926-927	/	_	
12-26	927-934	0106705	_	
12-27	935-942	relates	_	
12-28	943-952	primarily	_	
12-29	953-955	to	_	
12-30	956-957	a	_	
12-31	958-959	"	_	
12-32	960-961	.	_	
12-33	962-963	.	_	
12-34	964-965	.	_	
12-35	966-967	.	_	
12-36	968-969	a	_	
12-37	970-971	.	_	
12-38	971-975	beta	_	
12-39	975-976	.	_	

#Text=-tubulin isotype modified at cysteine residue 239 . . . " Thus, at page 3 of this published patent application, in defining a "beta-tubulin modifying agent," it describes such agent as follows: "A ".beta.
13-1	976-977	-	_	
13-2	977-984	tubulin	_	
13-3	985-992	isotype	_	
13-4	993-1001	modified	_	
13-5	1002-1004	at	_	
13-6	1005-1013	cysteine	_	
13-7	1014-1021	residue	_	
13-8	1022-1025	239	_	
13-9	1026-1027	.	_	
13-10	1028-1029	.	_	
13-11	1030-1031	.	_	
13-12	1032-1033	"	_	
13-13	1034-1038	Thus	_	
13-14	1038-1039	,	_	
13-15	1040-1042	at	_	
13-16	1043-1047	page	_	
13-17	1048-1049	3	_	
13-18	1050-1052	of	_	
13-19	1053-1057	this	_	
13-20	1058-1067	published	_	
13-21	1068-1074	patent	_	
13-22	1075-1086	application	_	
13-23	1086-1087	,	_	
13-24	1088-1090	in	_	
13-25	1091-1099	defining	_	
13-26	1100-1101	a	_	
13-27	1102-1103	"	_	
13-28	1103-1115	beta-tubulin	_	
13-29	1116-1125	modifying	_	
13-30	1126-1131	agent	_	
13-31	1131-1132	,	_	
13-32	1132-1133	"	_	
13-33	1134-1136	it	_	
13-34	1137-1146	describes	_	
13-35	1147-1151	such	_	
13-36	1152-1157	agent	_	
13-37	1158-1160	as	_	
13-38	1161-1168	follows	_	
13-39	1168-1169	:	_	
13-40	1170-1171	"	_	
13-41	1171-1172	A	_	
13-42	1173-1174	"	_	
13-43	1174-1175	.	_	
13-44	1175-1179	beta	_	
13-45	1179-1180	.	_	

#Text=-tubulin modifying agent" refers to an agent that has the ability to specifically react with an amino acid residue of .beta.
14-1	1180-1181	-	_	
14-2	1181-1188	tubulin	_	
14-3	1189-1198	modifying	_	
14-4	1199-1204	agent	_	
14-5	1204-1205	"	_	
14-6	1206-1212	refers	_	
14-7	1213-1215	to	_	
14-8	1216-1218	an	_	
14-9	1219-1224	agent	_	
14-10	1225-1229	that	_	
14-11	1230-1233	has	_	
14-12	1234-1237	the	_	
14-13	1238-1245	ability	_	
14-14	1246-1248	to	_	
14-15	1249-1261	specifically	_	
14-16	1262-1267	react	_	
14-17	1268-1272	with	_	
14-18	1273-1275	an	_	
14-19	1276-1281	amino	_	
14-20	1282-1286	acid	_	
14-21	1287-1294	residue	_	
14-22	1295-1297	of	_	
14-23	1298-1299	.	_	
14-24	1299-1303	beta	_	
14-25	1303-1304	.	_	

#Text=-tubulin, preferably a cysteine, more preferably the cysteine residue at position 239 of a .beta.
15-1	1304-1305	-	_	
15-2	1305-1312	tubulin	_	
15-3	1312-1313	,	_	
15-4	1314-1324	preferably	_	
15-5	1325-1326	a	_	
15-6	1327-1335	cysteine	_	
15-7	1335-1336	,	_	
15-8	1337-1341	more	_	
15-9	1342-1352	preferably	_	
15-10	1353-1356	the	_	
15-11	1357-1365	cysteine	_	
15-12	1366-1373	residue	_	
15-13	1374-1376	at	_	
15-14	1377-1385	position	_	
15-15	1386-1389	239	_	
15-16	1390-1392	of	_	
15-17	1393-1394	a	_	
15-18	1395-1396	.	_	
15-19	1396-1400	beta	_	
15-20	1400-1401	.	_	

#Text=-tubulin isotype such as .beta.1-.beta.2- or .beta.4-tubulin and antigenic fragments thereof comprising the residue, preferably cysteine 239.
16-1	1401-1402	-	_	
16-2	1402-1409	tubulin	_	
16-3	1410-1417	isotype	_	
16-4	1418-1422	such	_	
16-5	1423-1425	as	_	
16-6	1426-1427	.	_	
16-7	1427-1431	beta	_	
16-8	1431-1433	.1	_	
16-9	1433-1434	-	_	
16-10	1434-1435	.	_	
16-11	1435-1439	beta	_	
16-12	1439-1441	.2	_	
16-13	1441-1442	-	_	
16-14	1443-1445	or	_	
16-15	1446-1447	.	_	
16-16	1447-1451	beta	_	
16-17	1451-1453	.4	_	
16-18	1453-1454	-	_	
16-19	1454-1461	tubulin	_	
16-20	1462-1465	and	_	
16-21	1466-1475	antigenic	_	
16-22	1476-1485	fragments	_	
16-23	1486-1493	thereof	_	
16-24	1494-1504	comprising	_	
16-25	1505-1508	the	_	
16-26	1509-1516	residue	_	
16-27	1516-1517	,	_	
16-28	1518-1528	preferably	_	
16-29	1529-1537	cysteine	_	
16-30	1538-1541	239	_	
16-31	1541-1542	.	_	

#Text=The .beta.
17-1	1543-1546	The	_	
17-2	1547-1548	.	_	
17-3	1548-1552	beta	_	
17-4	1552-1553	.	_	

#Text=-tubulin modifying agent of the invention can be, e.g., any sulfhydryl or disulfide modifying agent known to those of skill in the art that has the ability to react with the sulfur group on a cysteine residue, preferably cysteine residue 239 of a .beta.
18-1	1553-1554	-	_	
18-2	1554-1561	tubulin	_	
18-3	1562-1571	modifying	_	
18-4	1572-1577	agent	_	
18-5	1578-1580	of	_	
18-6	1581-1584	the	_	
18-7	1585-1594	invention	_	
18-8	1595-1598	can	_	
18-9	1599-1601	be	_	
18-10	1601-1602	,	_	
18-11	1603-1606	e.g	_	
18-12	1606-1607	.	_	
18-13	1607-1608	,	_	
18-14	1609-1612	any	_	
18-15	1613-1623	sulfhydryl	_	
18-16	1624-1626	or	_	
18-17	1627-1636	disulfide	_	
18-18	1637-1646	modifying	_	
18-19	1647-1652	agent	_	
18-20	1653-1658	known	_	
18-21	1659-1661	to	_	
18-22	1662-1667	those	_	
18-23	1668-1670	of	_	
18-24	1671-1676	skill	_	
18-25	1677-1679	in	_	
18-26	1680-1683	the	_	
18-27	1684-1687	art	_	
18-28	1688-1692	that	_	
18-29	1693-1696	has	_	
18-30	1697-1700	the	_	
18-31	1701-1708	ability	_	
18-32	1709-1711	to	_	
18-33	1712-1717	react	_	
18-34	1718-1722	with	_	
18-35	1723-1726	the	_	
18-36	1727-1733	sulfur	_	
18-37	1734-1739	group	_	
18-38	1740-1742	on	_	
18-39	1743-1744	a	_	
18-40	1745-1753	cysteine	_	
18-41	1754-1761	residue	_	
18-42	1761-1762	,	_	
18-43	1763-1773	preferably	_	
18-44	1774-1782	cysteine	_	
18-45	1783-1790	residue	_	
18-46	1791-1794	239	_	
18-47	1795-1797	of	_	
18-48	1798-1799	a	_	
18-49	1800-1801	.	_	
18-50	1801-1805	beta	_	
18-51	1805-1806	.	_	

#Text=-tubulin isotype.
19-1	1806-1807	-	_	
19-2	1807-1814	tubulin	_	
19-3	1815-1822	isotype	_	
19-4	1822-1823	.	_	

#Text=Preferably, the .beta.
20-1	1824-1834	Preferably	_	
20-2	1834-1835	,	_	
20-3	1836-1839	the	_	
20-4	1840-1841	.	_	
20-5	1841-1845	beta	_	
20-6	1845-1846	.	_	

#Text=-tubulin modifying agents are substituted benzene compounds, pentafluorobenzenesulfonamides, arylsulfonanilide phosphates, and derivatives, analogs, and substituted compounds thereof (see, e.g., U.S.
21-1	1846-1847	-	_	
21-2	1847-1854	tubulin	_	
21-3	1855-1864	modifying	_	
21-4	1865-1871	agents	_	
21-5	1872-1875	are	_	
21-6	1876-1887	substituted	_	
21-7	1888-1895	benzene	_	
21-8	1896-1905	compounds	_	
21-9	1905-1906	,	_	
21-10	1907-1937	pentafluorobenzenesulfonamides	_	
21-11	1937-1938	,	_	
21-12	1939-1956	arylsulfonanilide	_	
21-13	1957-1967	phosphates	_	
21-14	1967-1968	,	_	
21-15	1969-1972	and	_	
21-16	1973-1984	derivatives	_	
21-17	1984-1985	,	_	
21-18	1986-1993	analogs	_	
21-19	1993-1994	,	_	
21-20	1995-1998	and	_	
21-21	1999-2010	substituted	_	
21-22	2011-2020	compounds	_	
21-23	2021-2028	thereof	_	
21-24	2029-2030	(	_	
21-25	2030-2033	see	_	
21-26	2033-2034	,	_	
21-27	2035-2038	e.g	_	
21-28	2038-2039	.	_	
21-29	2039-2040	,	_	
21-30	2041-2044	U.S	_	
21-31	2044-2045	.	_	

#Text=Pat.
22-1	2046-2049	Pat	_	
22-2	2049-2050	.	_	

#Text=No. 5,880,151; PCT 97/02926; PCT 97/12720; PCT 98/16781; PCT 99/13759; and PCT 99/16032, herein incorporated by reference; see also Pierce Catalogue, 1999/2000, and Means, Chemical Modification of Proteins).
23-1	2051-2053	No	_	
23-2	2053-2054	.	_	
23-3	2055-2064	5,880,151	_	
23-4	2064-2065	;	_	
23-5	2066-2069	PCT	_	
23-6	2070-2072	97	_	
23-7	2072-2073	/	_	
23-8	2073-2078	02926	_	
23-9	2078-2079	;	_	
23-10	2080-2083	PCT	_	
23-11	2084-2086	97	_	
23-12	2086-2087	/	_	
23-13	2087-2092	12720	_	
23-14	2092-2093	;	_	
23-15	2094-2097	PCT	_	
23-16	2098-2100	98	_	
23-17	2100-2101	/	_	
23-18	2101-2106	16781	_	
23-19	2106-2107	;	_	
23-20	2108-2111	PCT	_	
23-21	2112-2114	99	_	
23-22	2114-2115	/	_	
23-23	2115-2120	13759	_	
23-24	2120-2121	;	_	
23-25	2122-2125	and	_	
23-26	2126-2129	PCT	_	
23-27	2130-2132	99	_	
23-28	2132-2133	/	_	
23-29	2133-2138	16032	_	
23-30	2138-2139	,	_	
23-31	2140-2146	herein	_	
23-32	2147-2159	incorporated	_	
23-33	2160-2162	by	_	
23-34	2163-2172	reference	_	
23-35	2172-2173	;	_	
23-36	2174-2177	see	_	
23-37	2178-2182	also	_	
23-38	2183-2189	Pierce	_	
23-39	2190-2199	Catalogue	_	
23-40	2199-2200	,	_	
23-41	2201-2205	1999	_	
23-42	2205-2206	/	_	
23-43	2206-2210	2000	_	
23-44	2210-2211	,	_	
23-45	2212-2215	and	_	
23-46	2216-2221	Means	_	
23-47	2221-2222	,	_	
23-48	2223-2231	Chemical	_	
23-49	2232-2244	Modification	_	
23-50	2245-2247	of	_	
23-51	2248-2256	Proteins	_	
23-52	2256-2257	)	_	
23-53	2257-2258	.	_	

#Text=In one embodiment, the agent is 2-fluoro-1-methoxy-4-pentafluo- rophenylsulfonamidobenzene (compound 1; FIG. 1C).
24-1	2259-2261	In	_	
24-2	2262-2265	one	_	
24-3	2266-2276	embodiment	_	
24-4	2276-2277	,	_	
24-5	2278-2281	the	_	
24-6	2282-2287	agent	_	
24-7	2288-2290	is	_	
24-8	2291-2292	2	_	
24-9	2292-2293	-	_	
24-10	2293-2299	fluoro	_	
24-11	2299-2300	-	_	
24-12	2300-2301	1	_	
24-13	2301-2302	-	_	
24-14	2302-2309	methoxy	_	
24-15	2309-2310	-	_	
24-16	2310-2311	4	_	
24-17	2311-2312	-	_	
24-18	2312-2321	pentafluo	_	
24-19	2321-2322	-	_	
24-20	2323-2349	rophenylsulfonamidobenzene	_	
24-21	2350-2351	(	_	
24-22	2351-2359	compound	_	
24-23	2360-2361	1	_	
24-24	2361-2362	;	_	
24-25	2363-2366	FIG	_	
24-26	2366-2367	.	_	
24-27	2368-2370	1C	_	
24-28	2370-2371	)	_	
24-29	2371-2372	.	_	

#Text=Modification of a .beta.
25-1	2373-2385	Modification	_	
25-2	2386-2388	of	_	
25-3	2389-2390	a	_	
25-4	2391-2392	.	_	
25-5	2392-2396	beta	_	
25-6	2396-2397	.	_	

#Text=-tubulin isotype at an amino acid residue, e.g., cysteine 239, by an agent can be tested by treating a tubulin peptide, described herein, with the putative agent, followed by, e.g., elemental analysis for a halogen, e.g., fluorine, reverse phase HPLC, NMR, or sequencing and HPLC mass spectrometry.
26-1	2397-2398	-	_	
26-2	2398-2405	tubulin	_	
26-3	2406-2413	isotype	_	
26-4	2414-2416	at	_	
26-5	2417-2419	an	_	
26-6	2420-2425	amino	_	
26-7	2426-2430	acid	_	
26-8	2431-2438	residue	_	
26-9	2438-2439	,	_	
26-10	2440-2443	e.g	_	
26-11	2443-2444	.	_	
26-12	2444-2445	,	_	
26-13	2446-2454	cysteine	_	
26-14	2455-2458	239	_	
26-15	2458-2459	,	_	
26-16	2460-2462	by	_	
26-17	2463-2465	an	_	
26-18	2466-2471	agent	_	
26-19	2472-2475	can	_	
26-20	2476-2478	be	_	
26-21	2479-2485	tested	_	
26-22	2486-2488	by	_	
26-23	2489-2497	treating	_	
26-24	2498-2499	a	_	
26-25	2500-2507	tubulin	_	
26-26	2508-2515	peptide	_	
26-27	2515-2516	,	_	
26-28	2517-2526	described	_	
26-29	2527-2533	herein	_	
26-30	2533-2534	,	_	
26-31	2535-2539	with	_	
26-32	2540-2543	the	_	
26-33	2544-2552	putative	_	
26-34	2553-2558	agent	_	
26-35	2558-2559	,	_	
26-36	2560-2568	followed	_	
26-37	2569-2571	by	_	
26-38	2571-2572	,	_	
26-39	2573-2576	e.g	_	
26-40	2576-2577	.	_	
26-41	2577-2578	,	_	
26-42	2579-2588	elemental	_	
26-43	2589-2597	analysis	_	
26-44	2598-2601	for	_	
26-45	2602-2603	a	_	
26-46	2604-2611	halogen	_	
26-47	2611-2612	,	_	
26-48	2613-2616	e.g	_	
26-49	2616-2617	.	_	
26-50	2617-2618	,	_	
26-51	2619-2627	fluorine	_	
26-52	2627-2628	,	_	
26-53	2629-2636	reverse	_	
26-54	2637-2642	phase	_	
26-55	2643-2647	HPLC	_	
26-56	2647-2648	,	_	
26-57	2649-2652	NMR	_	
26-58	2652-2653	,	_	
26-59	2654-2656	or	_	
26-60	2657-2667	sequencing	_	
26-61	2668-2671	and	_	
26-62	2672-2676	HPLC	_	
26-63	2677-2681	mass	_	
26-64	2682-2694	spectrometry	_	
26-65	2694-2695	.	_	

#Text=Optionally compound 1 described herein can be used as a positive control.
27-1	2696-2706	Optionally	_	
27-2	2707-2715	compound	_	
27-3	2716-2717	1	_	
27-4	2718-2727	described	_	
27-5	2728-2734	herein	_	
27-6	2735-2738	can	_	
27-7	2739-2741	be	_	
27-8	2742-2746	used	_	
27-9	2747-2749	as	_	
27-10	2750-2751	a	_	
27-11	2752-2760	positive	_	
27-12	2761-2768	control	_	
27-13	2768-2769	.	_	

#Text=Similarly, an .alpha.
28-1	2770-2779	Similarly	_	
28-2	2779-2780	,	_	
28-3	2781-2783	an	_	
28-4	2784-2785	.	_	
28-5	2785-2790	alpha	_	
28-6	2790-2791	.	_	

#Text=-tubulin modifying agent refers to an agent having the ability to specifically modify an amino acid residue of an .alpha.
29-1	2791-2792	-	_	
29-2	2792-2799	tubulin	_	
29-3	2800-2809	modifying	_	
29-4	2810-2815	agent	_	
29-5	2816-2822	refers	_	
29-6	2823-2825	to	_	
29-7	2826-2828	an	_	
29-8	2829-2834	agent	_	
29-9	2835-2841	having	_	
29-10	2842-2845	the	_	
29-11	2846-2853	ability	_	
29-12	2854-2856	to	_	
29-13	2857-2869	specifically	_	
29-14	2870-2876	modify	_	
29-15	2877-2879	an	_	
29-16	2880-2885	amino	_	
29-17	2886-2890	acid	_	
29-18	2891-2898	residue	_	
29-19	2899-2901	of	_	
29-20	2902-2904	an	_	
29-21	2905-2906	.	_	
29-22	2906-2911	alpha	_	
29-23	2911-2912	.	_	

#Text=-tubulin."
#Text=[0251] U.S.
30-1	2912-2913	-	_	
30-2	2913-2920	tubulin	_	
30-3	2920-2921	.	_	
30-4	2921-2922	"	_	
30-5	2923-2924	[	_	
30-6	2924-2928	0251	_	
30-7	2928-2929	]	_	
30-8	2930-2933	U.S	_	
30-9	2933-2934	.	_	

#Text=Pat.
31-1	2935-2938	Pat	_	
31-2	2938-2939	.	_	

#Text=No. 6,541,509, the entire disclosure of which is hereby incorporated by reference into this specification, discloses a "method for treating neoplasis using combination chemotherapy." claim 1 of this patent describes: "A method of treating neoplasia in a subject in need of treatment, comprising administering to the subject an amount of paclitaxel effective to treat the neoplasia, in combination with an amount of discodermolide effective to treat the neoplasia, wherein a synergistic antineoplastic effect results."
32-1	2940-2942	No	_	
32-2	2942-2943	.	_	
32-3	2944-2953	6,541,509	_	
32-4	2953-2954	,	_	
32-5	2955-2958	the	_	
32-6	2959-2965	entire	_	
32-7	2966-2976	disclosure	_	
32-8	2977-2979	of	_	
32-9	2980-2985	which	_	
32-10	2986-2988	is	_	
32-11	2989-2995	hereby	_	
32-12	2996-3008	incorporated	_	
32-13	3009-3011	by	_	
32-14	3012-3021	reference	_	
32-15	3022-3026	into	_	
32-16	3027-3031	this	_	
32-17	3032-3045	specification	_	
32-18	3045-3046	,	_	
32-19	3047-3056	discloses	_	
32-20	3057-3058	a	_	
32-21	3059-3060	"	_	
32-22	3060-3066	method	_	
32-23	3067-3070	for	_	
32-24	3071-3079	treating	_	
32-25	3080-3089	neoplasis	_	
32-26	3090-3095	using	_	
32-27	3096-3107	combination	_	
32-28	3108-3120	chemotherapy	_	
32-29	3120-3121	.	_	
32-30	3121-3122	"	_	
32-31	3123-3128	claim	_	
32-32	3129-3130	1	_	
32-33	3131-3133	of	_	
32-34	3134-3138	this	_	
32-35	3139-3145	patent	_	
32-36	3146-3155	describes	_	
32-37	3155-3156	:	_	
32-38	3157-3158	"	_	
32-39	3158-3159	A	_	
32-40	3160-3166	method	_	
32-41	3167-3169	of	_	
32-42	3170-3178	treating	_	
32-43	3179-3188	neoplasia	_	
32-44	3189-3191	in	_	
32-45	3192-3193	a	_	
32-46	3194-3201	subject	_	
32-47	3202-3204	in	_	
32-48	3205-3209	need	_	
32-49	3210-3212	of	_	
32-50	3213-3222	treatment	_	
32-51	3222-3223	,	_	
32-52	3224-3234	comprising	_	
32-53	3235-3248	administering	_	
32-54	3249-3251	to	_	
32-55	3252-3255	the	_	
32-56	3256-3263	subject	_	
32-57	3264-3266	an	_	
32-58	3267-3273	amount	_	
32-59	3274-3276	of	_	
32-60	3277-3287	paclitaxel	_	
32-61	3288-3297	effective	_	
32-62	3298-3300	to	_	
32-63	3301-3306	treat	_	
32-64	3307-3310	the	_	
32-65	3311-3320	neoplasia	_	
32-66	3320-3321	,	_	
32-67	3322-3324	in	_	
32-68	3325-3336	combination	_	
32-69	3337-3341	with	_	
32-70	3342-3344	an	_	
32-71	3345-3351	amount	_	
32-72	3352-3354	of	_	
32-73	3355-3369	discodermolide	_	
32-74	3370-3379	effective	_	
32-75	3380-3382	to	_	
32-76	3383-3388	treat	_	
32-77	3389-3392	the	_	
32-78	3393-3402	neoplasia	_	
32-79	3402-3403	,	_	
32-80	3404-3411	wherein	_	
32-81	3412-3413	a	_	
32-82	3414-3425	synergistic	_	
32-83	3426-3440	antineoplastic	_	
32-84	3441-3447	effect	_	
32-85	3448-3455	results	_	
32-86	3455-3456	.	_	
32-87	3456-3457	"	_	

#Text=At column 6 of this patent, the patentees discuss how to determine synergy between two drugs.
33-1	3458-3460	At	_	
33-2	3461-3467	column	_	
33-3	3468-3469	6	_	
33-4	3470-3472	of	_	
33-5	3473-3477	this	_	
33-6	3478-3484	patent	_	
33-7	3484-3485	,	_	
33-8	3486-3489	the	_	
33-9	3490-3499	patentees	_	
33-10	3500-3507	discuss	_	
33-11	3508-3511	how	_	
33-12	3512-3514	to	_	
33-13	3515-3524	determine	_	
33-14	3525-3532	synergy	_	
33-15	3533-3540	between	_	
33-16	3541-3544	two	_	
33-17	3545-3550	drugs	_	
33-18	3550-3551	.	_	

#Text=They state that: One measure of synergy between two drugs is the combination index (CI) method of Chou and Talalay [37], which is based on the median-effect principle.
34-1	3552-3556	They	_	
34-2	3557-3562	state	_	
34-3	3563-3567	that	_	
34-4	3567-3568	:	_	
34-5	3569-3572	One	*[1]	
34-6	3573-3580	measure	*[1]	
34-7	3581-3583	of	*[1]	
34-8	3584-3591	synergy	*[1]	
34-9	3592-3599	between	*[1]	
34-10	3600-3603	two	*[1]	
34-11	3604-3609	drugs	*[1]	
34-12	3610-3612	is	*[1]	
34-13	3613-3616	the	*[1]	
34-14	3617-3628	combination	*[1]	
34-15	3629-3634	index	*[1]	
34-16	3635-3636	(	*[1]	
34-17	3636-3638	CI	*[1]	
34-18	3638-3639	)	*[1]	
34-19	3640-3646	method	*[1]	
34-20	3647-3649	of	*[1]	
34-21	3650-3654	Chou	*[1]	
34-22	3655-3658	and	*[1]	
34-23	3659-3666	Talalay	*[1]	
34-24	3667-3668	[	_	
34-25	3668-3670	37	_	
34-26	3670-3671	]	_	
34-27	3671-3672	,	_	
34-28	3673-3678	which	_	
34-29	3679-3681	is	_	
34-30	3682-3687	based	_	
34-31	3688-3690	on	_	
34-32	3691-3694	the	_	
34-33	3695-3708	median-effect	_	
34-34	3709-3718	principle	_	
34-35	3718-3719	.	_	

#Text=This method calculates the degree of synergy, additivity, or antagonism between two drugs at various levels of cytotoxicity.
35-1	3720-3724	This	*[2]	
35-2	3725-3731	method	*[2]	
35-3	3732-3742	calculates	_	
35-4	3743-3746	the	_	
35-5	3747-3753	degree	_	
35-6	3754-3756	of	_	
35-7	3757-3764	synergy	_	
35-8	3764-3765	,	_	
35-9	3766-3776	additivity	_	
35-10	3776-3777	,	_	
35-11	3778-3780	or	_	
35-12	3781-3791	antagonism	_	
35-13	3792-3799	between	_	
35-14	3800-3803	two	_	
35-15	3804-3809	drugs	_	
35-16	3810-3812	at	_	
35-17	3813-3820	various	_	
35-18	3821-3827	levels	_	
35-19	3828-3830	of	_	
35-20	3831-3843	cytotoxicity	_	
35-21	3843-3844	.	_	

#Text=Where the CI value is less than 1, there is synergy between the two drugs.
36-1	3845-3850	Where	_	
36-2	3851-3854	the	_	
36-3	3855-3857	CI	_	
36-4	3858-3863	value	_	
36-5	3864-3866	is	_	
36-6	3867-3871	less	_	
36-7	3872-3876	than	_	
36-8	3877-3878	1	_	
36-9	3878-3879	,	_	
36-10	3880-3885	there	_	
36-11	3886-3888	is	_	
36-12	3889-3896	synergy	_	
36-13	3897-3904	between	_	
36-14	3905-3908	the	_	
36-15	3909-3912	two	_	
36-16	3913-3918	drugs	_	
36-17	3918-3919	.	_	

#Text=Where the CI value is 1, there is an additive effect, but no synergistic effect.
37-1	3920-3925	Where	_	
37-2	3926-3929	the	_	
37-3	3930-3932	CI	_	
37-4	3933-3938	value	_	
37-5	3939-3941	is	_	
37-6	3942-3943	1	_	
37-7	3943-3944	,	_	
37-8	3945-3950	there	_	
37-9	3951-3953	is	_	
37-10	3954-3956	an	_	
37-11	3957-3965	additive	_	
37-12	3966-3972	effect	_	
37-13	3972-3973	,	_	
37-14	3974-3977	but	_	
37-15	3978-3980	no	_	
37-16	3981-3992	synergistic	_	
37-17	3993-3999	effect	_	
37-18	3999-4000	.	_	

#Text=CI values greater than 1 indicate antagonism.
38-1	4001-4003	CI	_	
38-2	4004-4010	values	_	
38-3	4011-4018	greater	_	
38-4	4019-4023	than	_	
38-5	4024-4025	1	_	
38-6	4026-4034	indicate	_	
38-7	4035-4045	antagonism	_	
38-8	4045-4046	.	_	

#Text=The smaller the CI value, the greater the synergistic effect.
39-1	4047-4050	The	_	
39-2	4051-4058	smaller	_	
39-3	4059-4062	the	_	
39-4	4063-4065	CI	_	
39-5	4066-4071	value	_	
39-6	4071-4072	,	_	
39-7	4073-4076	the	_	
39-8	4077-4084	greater	_	
39-9	4085-4088	the	_	
39-10	4089-4100	synergistic	_	
39-11	4101-4107	effect	_	
39-12	4107-4108	.	_	

#Text=Another measurement of synergy is the fractional inhibitory concentration (FIC) [48].
40-1	4109-4116	Another	_	
40-2	4117-4128	measurement	_	
40-3	4129-4131	of	_	
40-4	4132-4139	synergy	_	
40-5	4140-4142	is	_	
40-6	4143-4146	the	_	
40-7	4147-4157	fractional	_	
40-8	4158-4168	inhibitory	_	
40-9	4169-4182	concentration	_	
40-10	4183-4184	(	_	
40-11	4184-4187	FIC	_	
40-12	4187-4188	)	_	
40-13	4189-4190	[	_	
40-14	4190-4192	48	_	
40-15	4192-4193	]	_	
40-16	4193-4194	.	_	

#Text=This fractional value is determined by expressing the IC50 of a drug acting in combination, as a function of the IC50 of the drug acting alone.
41-1	4195-4199	This	_	
41-2	4200-4210	fractional	_	
41-3	4211-4216	value	_	
41-4	4217-4219	is	_	
41-5	4220-4230	determined	_	
41-6	4231-4233	by	_	
41-7	4234-4244	expressing	_	
41-8	4245-4248	the	_	
41-9	4249-4253	IC50	_	
41-10	4254-4256	of	_	
41-11	4257-4258	a	_	
41-12	4259-4263	drug	_	
41-13	4264-4270	acting	_	
41-14	4271-4273	in	_	
41-15	4274-4285	combination	_	
41-16	4285-4286	,	_	
41-17	4287-4289	as	_	
41-18	4290-4291	a	_	
41-19	4292-4300	function	_	
41-20	4301-4303	of	_	
41-21	4304-4307	the	_	
41-22	4308-4312	IC50	_	
41-23	4313-4315	of	_	
41-24	4316-4319	the	_	
41-25	4320-4324	drug	_	
41-26	4325-4331	acting	_	
41-27	4332-4337	alone	_	
41-28	4337-4338	.	_	

#Text=For two interacting drugs, the sum of the FIC value for each drug represents the measure of synergistic interaction.
42-1	4339-4342	For	_	
42-2	4343-4346	two	_	
42-3	4347-4358	interacting	_	
42-4	4359-4364	drugs	_	
42-5	4364-4365	,	_	
42-6	4366-4369	the	_	
42-7	4370-4373	sum	_	
42-8	4374-4376	of	_	
42-9	4377-4380	the	_	
42-10	4381-4384	FIC	_	
42-11	4385-4390	value	_	
42-12	4391-4394	for	_	
42-13	4395-4399	each	_	
42-14	4400-4404	drug	_	
42-15	4405-4415	represents	_	
42-16	4416-4419	the	_	
42-17	4420-4427	measure	_	
42-18	4428-4430	of	_	
42-19	4431-4442	synergistic	_	
42-20	4443-4454	interaction	_	
42-21	4454-4455	.	_	

#Text=Where the FIC is less than 1, there is synergy between the two drugs.
43-1	4456-4461	Where	_	
43-2	4462-4465	the	_	
43-3	4466-4469	FIC	_	
43-4	4470-4472	is	_	
43-5	4473-4477	less	_	
43-6	4478-4482	than	_	
43-7	4483-4484	1	_	
43-8	4484-4485	,	_	
43-9	4486-4491	there	_	
43-10	4492-4494	is	_	
43-11	4495-4502	synergy	_	
43-12	4503-4510	between	_	
43-13	4511-4514	the	_	
43-14	4515-4518	two	_	
43-15	4519-4524	drugs	_	
43-16	4524-4525	.	_	

#Text=An FIC value of 1 indicates an additive effect.
44-1	4526-4528	An	_	
44-2	4529-4532	FIC	_	
44-3	4533-4538	value	_	
44-4	4539-4541	of	_	
44-5	4542-4543	1	_	
44-6	4544-4553	indicates	_	
44-7	4554-4556	an	_	
44-8	4557-4565	additive	_	
44-9	4566-4572	effect	_	
44-10	4572-4573	.	_	

#Text=The smaller the FIC value, the greater the synergistic interaction.
45-1	4574-4577	The	_	
45-2	4578-4585	smaller	_	
45-3	4586-4589	the	_	
45-4	4590-4593	FIC	_	
45-5	4594-4599	value	_	
45-6	4599-4600	,	_	
45-7	4601-4604	the	_	
45-8	4605-4612	greater	_	
45-9	4613-4616	the	_	
45-10	4617-4628	synergistic	_	
45-11	4629-4640	interaction	_	
45-12	4640-4641	.	_	

#Text=In the method of the present invention, combination therapy using paclitaxel and discodermolide preferably results in an antineoplastic effect that is greater than additive, as determined by any of the measures of synergy known in the art."
46-1	4642-4644	In	_	
46-2	4645-4648	the	_	
46-3	4649-4655	method	_	
46-4	4656-4658	of	_	
46-5	4659-4662	the	_	
46-6	4663-4670	present	_	
46-7	4671-4680	invention	_	
46-8	4680-4681	,	_	
46-9	4682-4693	combination	_	
46-10	4694-4701	therapy	_	
46-11	4702-4707	using	_	
46-12	4708-4718	paclitaxel	_	
46-13	4719-4722	and	_	
46-14	4723-4737	discodermolide	_	
46-15	4738-4748	preferably	_	
46-16	4749-4756	results	_	
46-17	4757-4759	in	_	
46-18	4760-4762	an	_	
46-19	4763-4777	antineoplastic	_	
46-20	4778-4784	effect	_	
46-21	4785-4789	that	_	
46-22	4790-4792	is	_	
46-23	4793-4800	greater	_	
46-24	4801-4805	than	_	
46-25	4806-4814	additive	_	
46-26	4814-4815	,	_	
46-27	4816-4818	as	_	
46-28	4819-4829	determined	_	
46-29	4830-4832	by	_	
46-30	4833-4836	any	_	
46-31	4837-4839	of	_	
46-32	4840-4843	the	_	
46-33	4844-4852	measures	_	
46-34	4853-4855	of	_	
46-35	4856-4863	synergy	_	
46-36	4864-4869	known	_	
46-37	4870-4872	in	_	
46-38	4873-4876	the	_	
46-39	4877-4880	art	_	
46-40	4880-4881	.	_	
46-41	4881-4882	"	_	

#Text=The cited Chou et al. reference is an entited "Quantitative analysis of dose effect relationships: the combined effect of multiple drugs or enzyme inhibitors," Adv.
47-1	4883-4886	The	_	
47-2	4887-4892	cited	_	
47-3	4893-4897	Chou	_	
47-4	4898-4900	et	_	
47-5	4901-4903	al	_	
47-6	4903-4904	.	_	
47-7	4905-4914	reference	_	
47-8	4915-4917	is	_	
47-9	4918-4920	an	_	
47-10	4921-4928	entited	_	
47-11	4929-4930	"	_	
47-12	4930-4942	Quantitative	_	
47-13	4943-4951	analysis	_	
47-14	4952-4954	of	_	
47-15	4955-4959	dose	_	
47-16	4960-4966	effect	_	
47-17	4967-4980	relationships	_	
47-18	4980-4981	:	_	
47-19	4982-4985	the	_	
47-20	4986-4994	combined	_	
47-21	4995-5001	effect	_	
47-22	5002-5004	of	_	
47-23	5005-5013	multiple	_	
47-24	5014-5019	drugs	_	
47-25	5020-5022	or	_	
47-26	5023-5029	enzyme	_	
47-27	5030-5040	inhibitors	_	
47-28	5040-5041	,	_	
47-29	5041-5042	"	_	
47-30	5043-5046	Adv	_	
47-31	5046-5047	.	_	

#Text=Enzyme Regul., 11:27-56 (1984).
48-1	5048-5054	Enzyme	_	
48-2	5055-5060	Regul	_	
48-3	5060-5061	.	_	
48-4	5061-5062	,	_	
48-5	5063-5065	11	_	
48-6	5065-5066	:	_	
48-7	5066-5068	27	_	
48-8	5068-5069	-	_	
48-9	5069-5071	56	_	
48-10	5072-5073	(	_	
48-11	5073-5077	1984	_	
48-12	5077-5078	)	_	
48-13	5078-5079	.	_	

#Text=The cited "reference 48 is an article by Hall et al., "The fractional inhibitory concentration (FIC) as a measure of synergy," J.
49-1	5080-5083	The	_	
49-2	5084-5089	cited	_	
49-3	5090-5091	"	_	
49-4	5091-5100	reference	_	
49-5	5101-5103	48	_	
49-6	5104-5106	is	_	
49-7	5107-5109	an	_	
49-8	5110-5117	article	_	
49-9	5118-5120	by	_	
49-10	5121-5125	Hall	_	
49-11	5126-5128	et	_	
49-12	5129-5131	al	_	
49-13	5131-5132	.	_	
49-14	5132-5133	,	_	
49-15	5134-5135	"	_	
49-16	5135-5138	The	_	
49-17	5139-5149	fractional	_	
49-18	5150-5160	inhibitory	_	
49-19	5161-5174	concentration	_	
49-20	5175-5176	(	_	
49-21	5176-5179	FIC	_	
49-22	5179-5180	)	_	
49-23	5181-5183	as	_	
49-24	5184-5185	a	_	
49-25	5186-5193	measure	_	
49-26	5194-5196	of	_	
49-27	5197-5204	synergy	_	
49-28	5204-5205	,	_	
49-29	5205-5206	"	_	
49-30	5207-5208	J	_	
49-31	5208-5209	.	_	

#Text=Antimicrob.
50-1	5210-5220	Antimicrob	_	
50-2	5220-5221	.	_	

#Text=Chemother., 11(5):427-433 (1983).
#Text=[0252] Claim 8 of U.S.
51-1	5222-5231	Chemother	_	
51-2	5231-5232	.	_	
51-3	5232-5233	,	_	
51-4	5234-5236	11	_	
51-5	5236-5237	(	_	
51-6	5237-5238	5	_	
51-7	5238-5239	)	_	
51-8	5239-5240	:	_	
51-9	5240-5243	427	_	
51-10	5243-5244	-	_	
51-11	5244-5247	433	_	
51-12	5248-5249	(	_	
51-13	5249-5253	1983	_	
51-14	5253-5254	)	_	
51-15	5254-5255	.	_	
51-16	5256-5257	[	_	
51-17	5257-5261	0252	_	
51-18	5261-5262	]	_	
51-19	5263-5268	Claim	_	
51-20	5269-5270	8	_	
51-21	5271-5273	of	_	
51-22	5274-5277	U.S	_	
51-23	5277-5278	.	_	

#Text=Pat.
52-1	5279-5282	Pat	_	
52-2	5282-5283	.	_	

#Text=No. 6,541,509 describes "A synergistic combination of antineoplastic agents, comprising an effective antimenoplastic amount of paclitaxel and an effective antineoplastic amount of discodermolide."
53-1	5284-5286	No	_	
53-2	5286-5287	.	_	
53-3	5288-5297	6,541,509	_	
53-4	5298-5307	describes	_	
53-5	5308-5309	"	_	
53-6	5309-5310	A	_	
53-7	5311-5322	synergistic	_	
53-8	5323-5334	combination	_	
53-9	5335-5337	of	_	
53-10	5338-5352	antineoplastic	_	
53-11	5353-5359	agents	_	
53-12	5359-5360	,	_	
53-13	5361-5371	comprising	_	
53-14	5372-5374	an	_	
53-15	5375-5384	effective	_	
53-16	5385-5400	antimenoplastic	_	
53-17	5401-5407	amount	_	
53-18	5408-5410	of	_	
53-19	5411-5421	paclitaxel	_	
53-20	5422-5425	and	_	
53-21	5426-5428	an	_	
53-22	5429-5438	effective	_	
53-23	5439-5453	antineoplastic	_	
53-24	5454-5460	amount	_	
53-25	5461-5463	of	_	
53-26	5464-5478	discodermolide	_	
53-27	5478-5479	.	_	
53-28	5479-5480	"	_	

#Text=As one embodiment of the instant invention, applicants claims: A synergistic combination of antineoplastic agents, comprising an effective antimenoplastic amount of paclitaxel and an effective antineoplastic amount of the preferred, magnetic anti-mitotic compound of this inventon.
54-1	5481-5483	As	_	
54-2	5484-5487	one	_	
54-3	5488-5498	embodiment	_	
54-4	5499-5501	of	_	
54-5	5502-5505	the	_	
54-6	5506-5513	instant	_	
54-7	5514-5523	invention	_	
54-8	5523-5524	,	_	
54-9	5525-5535	applicants	_	
54-10	5536-5542	claims	_	
54-11	5542-5543	:	_	
54-12	5544-5545	A	_	
54-13	5546-5557	synergistic	_	
54-14	5558-5569	combination	_	
54-15	5570-5572	of	_	
54-16	5573-5587	antineoplastic	_	
54-17	5588-5594	agents	_	
54-18	5594-5595	,	_	
54-19	5596-5606	comprising	_	
54-20	5607-5609	an	_	
54-21	5610-5619	effective	_	
54-22	5620-5635	antimenoplastic	_	
54-23	5636-5642	amount	_	
54-24	5643-5645	of	_	
54-25	5646-5656	paclitaxel	_	
54-26	5657-5660	and	_	
54-27	5661-5663	an	_	
54-28	5664-5673	effective	_	
54-29	5674-5688	antineoplastic	_	
54-30	5689-5695	amount	_	
54-31	5696-5698	of	_	
54-32	5699-5702	the	_	
54-33	5703-5712	preferred	_	
54-34	5712-5713	,	_	
54-35	5714-5722	magnetic	_	
54-36	5723-5735	anti-mitotic	_	
54-37	5736-5744	compound	_	
54-38	5745-5747	of	_	
54-39	5748-5752	this	_	
54-40	5753-5761	inventon	_	
54-41	5761-5762	.	_	

#Text=Thus, the process of such U.S.
55-1	5763-5767	Thus	_	
55-2	5767-5768	,	_	
55-3	5769-5772	the	_	
55-4	5773-5780	process	_	
55-5	5781-5783	of	_	
55-6	5784-5788	such	_	
55-7	5789-5792	U.S	_	
55-8	5792-5793	.	_	

#Text=Pat.
56-1	5794-5797	Pat	_	
56-2	5797-5798	.	_	

#Text=No. 6,541,509 may be adapted to use the magnetic compound of this invention instead of discodermolide.
#Text=[0253] As is disclosed in U.S.
57-1	5799-5801	No	_	
57-2	5801-5802	.	_	
57-3	5803-5812	6,541,509	_	
57-4	5813-5816	may	_	
57-5	5817-5819	be	_	
57-6	5820-5827	adapted	_	
57-7	5828-5830	to	_	
57-8	5831-5834	use	_	
57-9	5835-5838	the	_	
57-10	5839-5847	magnetic	_	
57-11	5848-5856	compound	_	
57-12	5857-5859	of	_	
57-13	5860-5864	this	_	
57-14	5865-5874	invention	_	
57-15	5875-5882	instead	_	
57-16	5883-5885	of	_	
57-17	5886-5900	discodermolide	_	
57-18	5900-5901	.	_	
57-19	5902-5903	[	_	
57-20	5903-5907	0253	_	
57-21	5907-5908	]	_	
57-22	5909-5911	As	_	
57-23	5912-5914	is	_	
57-24	5915-5924	disclosed	_	
57-25	5925-5927	in	_	
57-26	5928-5931	U.S	_	
57-27	5931-5932	.	_	

#Text=Pat.
58-1	5933-5936	Pat	_	
58-2	5936-5937	.	_	

#Text=No. 6,541,509, "The present invention provides a method of treating neoplasia in a subject in need of treatment.
59-1	5938-5940	No	_	
59-2	5940-5941	.	_	
59-3	5942-5951	6,541,509	_	
59-4	5951-5952	,	_	
59-5	5953-5954	"	_	
59-6	5954-5957	The	_	
59-7	5958-5965	present	_	
59-8	5966-5975	invention	_	
59-9	5976-5984	provides	_	
59-10	5985-5986	a	_	
59-11	5987-5993	method	_	
59-12	5994-5996	of	_	
59-13	5997-6005	treating	_	
59-14	6006-6015	neoplasia	_	
59-15	6016-6018	in	_	
59-16	6019-6020	a	_	
59-17	6021-6028	subject	_	
59-18	6029-6031	in	_	
59-19	6032-6036	need	_	
59-20	6037-6039	of	_	
59-21	6040-6049	treatment	_	
59-22	6049-6050	.	_	

#Text=As used herein, `neoplasia` refers to the uncontrolled and progressive multiplication of cells under conditions that would not elicit, or would cause cessation of, multiplication of normal cells.
60-1	6051-6053	As	_	
60-2	6054-6058	used	_	
60-3	6059-6065	herein	_	
60-4	6065-6066	,	_	
60-5	6067-6068	`	_	
60-6	6068-6077	neoplasia	_	
60-7	6077-6078	`	_	
60-8	6079-6085	refers	_	
60-9	6086-6088	to	_	
60-10	6089-6092	the	_	
60-11	6093-6105	uncontrolled	_	
60-12	6106-6109	and	_	
60-13	6110-6121	progressive	_	
60-14	6122-6136	multiplication	_	
60-15	6137-6139	of	_	
60-16	6140-6145	cells	_	
60-17	6146-6151	under	_	
60-18	6152-6162	conditions	_	
60-19	6163-6167	that	_	
60-20	6168-6173	would	_	
60-21	6174-6177	not	_	
60-22	6178-6184	elicit	_	
60-23	6184-6185	,	_	
60-24	6186-6188	or	_	
60-25	6189-6194	would	_	
60-26	6195-6200	cause	_	
60-27	6201-6210	cessation	_	
60-28	6211-6213	of	_	
60-29	6213-6214	,	_	
60-30	6215-6229	multiplication	_	
60-31	6230-6232	of	_	
60-32	6233-6239	normal	_	
60-33	6240-6245	cells	_	
60-34	6245-6246	.	_	

#Text=Neoplasia results in the formation of a `neoplasm`, which is defined herein to mean any new and abnormal growth, particularly a new growth of tissue, in which the growth is uncontrolled and progressive.
61-1	6247-6256	Neoplasia	_	
61-2	6257-6264	results	_	
61-3	6265-6267	in	_	
61-4	6268-6271	the	_	
61-5	6272-6281	formation	_	
61-6	6282-6284	of	_	
61-7	6285-6286	a	_	
61-8	6287-6288	`	_	
61-9	6288-6296	neoplasm	_	
61-10	6296-6297	`	_	
61-11	6297-6298	,	_	
61-12	6299-6304	which	_	
61-13	6305-6307	is	_	
61-14	6308-6315	defined	_	
61-15	6316-6322	herein	_	
61-16	6323-6325	to	_	
61-17	6326-6330	mean	_	
61-18	6331-6334	any	_	
61-19	6335-6338	new	_	
61-20	6339-6342	and	_	
61-21	6343-6351	abnormal	_	
61-22	6352-6358	growth	_	
61-23	6358-6359	,	_	
61-24	6360-6372	particularly	_	
61-25	6373-6374	a	_	
61-26	6375-6378	new	_	
61-27	6379-6385	growth	_	
61-28	6386-6388	of	_	
61-29	6389-6395	tissue	_	
61-30	6395-6396	,	_	
61-31	6397-6399	in	_	
61-32	6400-6405	which	_	
61-33	6406-6409	the	_	
61-34	6410-6416	growth	_	
61-35	6417-6419	is	_	
61-36	6420-6432	uncontrolled	_	
61-37	6433-6436	and	_	
61-38	6437-6448	progressive	_	
61-39	6448-6449	.	_	

#Text=Malignant neoplasms are distinguished from benign in that the former show a greater degree of anaplasia, or loss of differentiation and orientation of cells, and have the properties of invasion and metastasis.
62-1	6450-6459	Malignant	_	
62-2	6460-6469	neoplasms	_	
62-3	6470-6473	are	_	
62-4	6474-6487	distinguished	_	
62-5	6488-6492	from	_	
62-6	6493-6499	benign	_	
62-7	6500-6502	in	_	
62-8	6503-6507	that	_	
62-9	6508-6511	the	_	
62-10	6512-6518	former	_	
62-11	6519-6523	show	_	
62-12	6524-6525	a	_	
62-13	6526-6533	greater	_	
62-14	6534-6540	degree	_	
62-15	6541-6543	of	_	
62-16	6544-6553	anaplasia	_	
62-17	6553-6554	,	_	
62-18	6555-6557	or	_	
62-19	6558-6562	loss	_	
62-20	6563-6565	of	_	
62-21	6566-6581	differentiation	_	
62-22	6582-6585	and	_	
62-23	6586-6597	orientation	_	
62-24	6598-6600	of	_	
62-25	6601-6606	cells	_	
62-26	6606-6607	,	_	
62-27	6608-6611	and	_	
62-28	6612-6616	have	_	
62-29	6617-6620	the	_	
62-30	6621-6631	properties	_	
62-31	6632-6634	of	_	
62-32	6635-6643	invasion	_	
62-33	6644-6647	and	_	
62-34	6648-6658	metastasis	_	
62-35	6658-6659	.	_	

#Text=Thus, neoplasia includes `cancer`, which herein refers to a proliferation of cells having the unique trait of loss of normal controls, resulting in unregulated growth, lack of differentiation, local tissue invasion, and metastasis."
63-1	6660-6664	Thus	_	
63-2	6664-6665	,	_	
63-3	6666-6675	neoplasia	_	
63-4	6676-6684	includes	_	
63-5	6685-6686	`	_	
63-6	6686-6692	cancer	_	
63-7	6692-6693	`	_	
63-8	6693-6694	,	_	
63-9	6695-6700	which	_	
63-10	6701-6707	herein	_	
63-11	6708-6714	refers	_	
63-12	6715-6717	to	_	
63-13	6718-6719	a	_	
63-14	6720-6733	proliferation	_	
63-15	6734-6736	of	_	
63-16	6737-6742	cells	_	
63-17	6743-6749	having	_	
63-18	6750-6753	the	_	
63-19	6754-6760	unique	_	
63-20	6761-6766	trait	_	
63-21	6767-6769	of	_	
63-22	6770-6774	loss	_	
63-23	6775-6777	of	_	
63-24	6778-6784	normal	_	
63-25	6785-6793	controls	_	
63-26	6793-6794	,	_	
63-27	6795-6804	resulting	_	
63-28	6805-6807	in	_	
63-29	6808-6819	unregulated	_	
63-30	6820-6826	growth	_	
63-31	6826-6827	,	_	
63-32	6828-6832	lack	_	
63-33	6833-6835	of	_	
63-34	6836-6851	differentiation	_	
63-35	6851-6852	,	_	
63-36	6853-6858	local	_	
63-37	6859-6865	tissue	_	
63-38	6866-6874	invasion	_	
63-39	6874-6875	,	_	
63-40	6876-6879	and	_	
63-41	6880-6890	metastasis	_	
63-42	6890-6891	.	_	
63-43	6891-6892	"	_	

#Text=As support for this statement, the patent cited a work by Beers and Berkow (eds.), The Merck Manual of Diagnosis and Therapy, 17.sup.th edition (Whitehouse Station, N.J.; Merck Research Laboratories, 1999, 973-974, 976, 986, and 991).
64-1	6893-6895	As	_	
64-2	6896-6903	support	_	
64-3	6904-6907	for	_	
64-4	6908-6912	this	_	
64-5	6913-6922	statement	_	
64-6	6922-6923	,	_	
64-7	6924-6927	the	_	
64-8	6928-6934	patent	_	
64-9	6935-6940	cited	_	
64-10	6941-6942	a	_	
64-11	6943-6947	work	_	
64-12	6948-6950	by	_	
64-13	6951-6956	Beers	_	
64-14	6957-6960	and	_	
64-15	6961-6967	Berkow	_	
64-16	6968-6969	(	_	
64-17	6969-6972	eds	_	
64-18	6972-6973	.	_	
64-19	6973-6974	)	_	
64-20	6974-6975	,	_	
64-21	6976-6979	The	_	
64-22	6980-6985	Merck	_	
64-23	6986-6992	Manual	_	
64-24	6993-6995	of	_	
64-25	6996-7005	Diagnosis	_	
64-26	7006-7009	and	_	
64-27	7010-7017	Therapy	_	
64-28	7017-7018	,	_	
64-29	7019-7021	17	_	
64-30	7021-7022	.	_	
64-31	7022-7028	sup.th	_	
64-32	7029-7036	edition	_	
64-33	7037-7038	(	_	
64-34	7038-7048	Whitehouse	_	
64-35	7049-7056	Station	_	
64-36	7056-7057	,	_	
64-37	7058-7061	N.J	_	
64-38	7061-7062	.	_	
64-39	7062-7063	;	_	
64-40	7064-7069	Merck	_	
64-41	7070-7078	Research	_	
64-42	7079-7091	Laboratories	_	
64-43	7091-7092	,	_	
64-44	7093-7097	1999	_	
64-45	7097-7098	,	_	
64-46	7099-7102	973	_	
64-47	7102-7103	-	_	
64-48	7103-7106	974	_	
64-49	7106-7107	,	_	
64-50	7108-7111	976	_	
64-51	7111-7112	,	_	
64-52	7113-7116	986	_	
64-53	7116-7117	,	_	
64-54	7118-7121	and	_	
64-55	7122-7125	991	_	
64-56	7125-7126	)	_	
64-57	7126-7127	.	_	
